Genetically speaking, more than 90% of HHT patients show mutations in ENG or ACVRL1/ALK1 genes, both belonging to the TGF-β/BMP9 signaling pathway. The gene discussed is GDF2; the disease is hereditary hemorrhagic telangiectasia.